$1700 | SAVE $300 | Single User
$3400 | SAVE $600 | Site License
$5100 | SAVE $900 | Enterprise License

Thalassemia - Pipeline Review, H1 2018

Thalassemia - Pipeline Review, H1 2018
[Lowest Price Guaranteed: $1,700]

Published by Global Markets Direct: 27 Feb 2018 | 194773 | In Stock
Related Topics: Healthcare

Introduction

Thalassemia - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 7, 5, 3, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Thalassemia - Pipeline Review, H1 2018

  • Table of Contents

    Table of Contents 2

    Introduction 4

    Thalassemia - Overview 5

    Thalassemia - Therapeutics Development 6

    Thalassemia - Therapeutics Assessment 14

    Thalassemia - Companies Involved in Therapeutics Development 22

    Thalassemia - Drug Profiles 32

    Thalassemia - Dormant Projects 129

    Thalassemia - Product Development Milestones 130

    Appendix 143

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

194773 | GMDHC10203IDB

Number of Pages

148

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Thalassemia -Epidemiology Forecast to 2025
DelveInsight “Thalassemia - Epidemiology Forecast To 2025” provides an overview of the epidemiology ...
10 Oct 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Thalassemia - Market Insights, Epidemiology and Market Forecast – 2025
DelveInsight’s “Thalassemia - Market Insights, Epidemiology and Market Forecast - Market Insights, E...
10 Oct 2017 by Delve Insight USD $4,888 (normally
USD $5,751)
More Info
SAVE 15% today! Thalassemia - Pipeline Review, H2 2017
Thalassemia - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Aug 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Thalassemia - Pipeline Review, H2 2017
Thalassemia - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Aug 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Thalassemia - Epidemiology Forecast To 2023
DelveInsight “Thalassemia - Epidemiology Forecast To 2023” provides an overview of the epidemiology ...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Thalassemia-Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Thalassemia - Market Insigh...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Thalassemia-Pipeline Insights, 2017
DelveInsight’s, “ Thalassemia-Pipeline Insights, 2017”, report provides in depth insights on the pip...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Thalassemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Thalassemia - Pipeline Review, H1 2017
Thalassemia - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healt...
22 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Thalassemia Global Clinical Trials Review, H2, 2016
Thalassemia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Thala...
31 Aug 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Thalassemia - Pipeline Review, H1 2018 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...